Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2022.3203
Abstract: Importance Although P2Y12 inhibitor monotherapy after a minimum period of dual antiplatelet therapy (DAPT) is a well-known way to reduce the risk of bleeding after percutaneous coronary intervention (PCI), data comparing long-term clinical outcomes between… read more here.
Keywords: p2y12 inhibitor; long term; inhibitor monotherapy; trial ... See more keywords
P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-020-00947-x
Abstract: Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) reduces the incidence of thrombotic events but increases the risk of bleeding, which is associated with a substantial and durable risk of death and could offset… read more here.
Keywords: monotherapy short; p2y12 inhibitor; term; inhibitor monotherapy ... See more keywords
Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2019.01.001
Abstract: PURPOSE The aim of this study was to systematically evaluate the effect of sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy on the weight of patients with type 2 diabetes mellitus (T2DM) and to compare different SGLT2… read more here.
Keywords: sglt2 inhibitors; weight; inhibitor monotherapy; meta analysis ... See more keywords
P2Y12 INHIBITOR MONOTHERAPY AFTER A SHORT DUAL ANTIPLATELET THERAPY VS. 12-MONTH DUAL ANTIPLATELET THERAPY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)30700-2
Abstract: Dual Antiplatelet Therapy (DAPT) after PCI reduces the incidence of thrombotic events but increases the risk of bleeding, which is associated with a substantial and durable risk of death and could offset the benefits of… read more here.
Keywords: p2y12 inhibitor; dual antiplatelet; inhibitor monotherapy; antiplatelet therapy ... See more keywords
Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14421
Abstract: BACKGROUND Adipose tissue induces inflammation, which desensitizes the efficacy of immunotherapy. However, several reports show that the therapeutic effect of programed cell death 1 (PD-1)/programed death-ligand 1 (PD-L1) inhibitor(s) monotherapy is significantly better in obese… read more here.
Keywords: adipose tissue; cancer; cell; tissue ... See more keywords
Maintained P2Y12 inhibitor monotherapy after shorter-duration of dual antiplatelet therapy in patients undergoing coronary drug-eluting stents implantation: An updated meta-analysis of randomized trials.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of clinical pharmacy and therapeutics"
DOI: 10.1111/jcpt.13626
Abstract: WHAT IS KNOWN AND OBJECTIVE It is well known that high in-stent thrombotic risk due to the superimposition of a platelet-rich thrombus was considered as the main origin of major adverse cardiac events after stent… read more here.
Keywords: inhibitor monotherapy; antiplatelet; p2y12 inhibitor; antiplatelet therapy ... See more keywords
Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23094549
Abstract: Increasing evidence has shown P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after percutaneous coronary intervention (PCI) with stent implantation in the modern era. However, patients with diabetes mellitus (DM) have a higher… read more here.
Keywords: p2y12 inhibitor; bleeding events; inhibitor monotherapy; risk ... See more keywords
P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceuticals"
DOI: 10.3390/ph16020232
Abstract: P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after percutaneous coronary intervention (PCI) in the modern era. Clinical trials have shown that it could lower the risk of bleeding complications without increased ischemic… read more here.
Keywords: p2y12 inhibitor; monotherapy; meta analysis; inhibitor monotherapy ... See more keywords